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Background. Evaluating diagnostic and early detection biomarkers requires comparing serum protein concentrations among
biosamples ascertained from subjects with and without cancer. Efforts are generally made to standardize blood processing and
storage conditions for cases and controls, but blood sample collection conditions cannot be completely controlled. For
example, blood samples from cases are often obtained from persons aware of their diagnoses, and collected after fasting or in
surgery, whereas blood samples from some controls may be obtained in different conditions, such as a clinic visit. By
measuring the effects of differences in collection conditions on three different markers, we investigated the potential of these
effects to bias validation studies. Methodology and Principle Findings. We analyzed serum concentrations of three
previously studied putative ovarian cancer serum biomarkers–CA 125, Prolactin and MIF–in healthy women, women with
ovarian cancer undergoing gynecologic surgery, women undergoing surgery for benign ovary pathology, and women
undergoing surgery with pathologically normal ovaries. For women undergoing surgery, a blood sample was collected either
in the clinic 1 to 39 days prior to surgery, or on the day of surgery after anesthesia was administered but prior to the surgical
procedure, or both. We found that one marker, prolactin, was dramatically affected by collection conditions, while CA 125 and
MIF were unaffected. Prolactin levels were not different between case and control groups after accounting for the conditions
of sample collection, suggesting that sample ascertainment could explain some or all of the previously reported results about
its potential as a biomarker for ovarian cancer. Conclusions. Biomarker validation studies should use standardized collection
conditions, use multiple control groups, and/or collect samples from cases prior to influence of diagnosis whenever feasible to
detect and correct for potential biases associated with sample collection.
Citation: Thorpe JD, Duan X, Forrest R, Lowe K, Brown L, et al (2007) Effects of Blood Collection Conditions on Ovarian Cancer Serum Markers. PLoS
ONE 2(12): e1281. doi:10.1371/journal.pone.0001281
INTRODUCTION
We hypothesize that even with identical sample processing and
storage protocols the environment and conditions of sample
collection can affect the levels of biomarkers, and that these potential
biases should be anticipated in biomarker validation study design.
Specifically,theenvironmentsurroundingdiagnosisandcollectionof
specimens from cases, such as surgical preparation, may affect blood
chemistry in a way that introduces systematic changes that may be
mistakenly attributed to the disease state. We demonstrate these
effects by evaluating conditions of blood collection in one established
and two novel ovarian cancer serum markers: CA 125, Prolactin,
and Macrophage Migration Inhibitory Factor (MIF). We show that
CA 125 and MIF behave as previously reported but that prolactin’s
performance is strongly affected by biases in sample ascertainment.
Cancer early detection biomarker validation studies are
designed to determine which proteins can distinguish between
healthy people and those with cancer. In contrast, a diagnostic
marker intends to distinguish between people with cancer and
those with benign conditions. To potentially impact cancer
mortality a marker must show abnormal levels in the blood of
cases compared to their appropriate controls, and for early
detection purposes they must elevate early enough in the disease
process to identify the disease at an early and more treatable state
[1]. Evaluating a protein in pre-clinical specimens collected well
before suspicion or diagnosis of cancer would be ideal for early
detection studies, whereas samples obtained at clinical presenta-
tion of disease are most relevant for diagnostic markers. However,
because pre-clinical specimens are seldom available, especially for
rare diseases, first-phase early detection validation studies often
seek to determine whether or not a marker can distinguish persons
with symptomatic disease from healthy controls prior to further
investment [2].
The primary intent of our biomarker validation study is to
ascertain to what extent the classification performance of a
biomarker can be attributed to disease associated response rather
than to ascertainment biases in sample collection. It is common to
construct case and control groups that are matched on sample
collection protocols, storage duration, subject age, and other
epidemiological information, in order to reduce potential biases
related to these factors. Less emphasis has been placed on using
multiple sources of control or case groups in order to detect
potential biases or on using procedures that may adjust for biases,
such as conditions of sample collection. In this manuscript we
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tion studies using multiple sources of well annotated case and
control groups. We demonstrate that prolactin is highly sensitive to
the conditions of collection: after adjusting for the conditions of
collection the marker is no longer considered a viable candidate.
CA 125 and MIF are shown to not be highly susceptible to these
conditions.
We selected three markers–CA 125, Prolactin and MIF–to
evaluate in a highly annotated set of case and control specimens.
CA 125 is a mucin-like glycoprotein which has been shown to
be elevated in most women with OC compared to a healthy
population [3]. CA 125 has also been evaluated in preclinical
serum specimens, and each study suggests that CA 125 is a
predictive marker that becomes increasingly powerful with
proximity to diagnosis [4–6]. However, CA 125 is also elevated
in several benign conditions and may also be a marker of
inflammation [7]. Due to insufficient sensitivity and specificity,
CA125 is not used clinically as a stand alone screening test. Falling
CA 125 levels after treatment are used to confirm response to
specific treatments [8] and elevating CA 125 levels signal
recurrence [9]. CA 125 is a ligand of Mesothelin [10], which
may play a role in the metastasis of OC to the peritoneum [11].
MIF is a proinflammatory cytokine which has been identified as
a candidate early detection marker for OC [12], although analysis
of its performance as a biomarker for early stage ovarian cancer
suggested that it does not exhibit higher sensitivity or specificity
than CA 125 [13]. Inhibition of the anti-inflammatory properties
of glucocorticoids is an important effect of MIF [14,15]. MIF may
also mediate some of the stimulatory effects of inflammation on
cancer progression. Evidence of MIF’s role in the regulation of
tumor-suppressor genes such as p53 [16,17] and angiogenesis
[18,19] points to a potential link between chronic inflammation
and the development of cancer.
Prolactin has been identified as a candidate early detection
marker for ovarian cancer with reports of impressively high
sensitivity (.90%) and specificity (.98%) [12]. Elevated levels of
circulating prolactin (hyperprolactinemia) have long been associ-
ated with pituitary tumors [20], but more recently prolactin has
been reported in association with a variety of additional cancers,
including breast [21–23], prostate [24], and colon carcinoma [25].
METHODS
Study population and serum specimen collection
Serum samples were collected by the Pacific Ovarian Cancer
Research Consortium for use in biomarker validation experiments.
The samples used in this study were collected at Swedish Medical
Center or Virginia Mason Hospital (Seattle, WA, USA) between
July 1, 2004 and June 30, 2006. Participants were recruited from
the following populations: apparently healthy women attending
regular breast cancer screening exams (healthy controls), women
undergoing gynecologic surgery for a variety of conditions but
with normal ovarian pathology (surgical controls), women without
malignancy but with benign ovarian disease (benign controls), and
women diagnosed with ovarian cancer, fallopian tube cancer, or
primary peritoneal invasive cancer. Identical specimen processing
protocols were used for all groups.
A sample of subjects from each of these conditions was selected
for biomarker validation studies. Patients with prior oophorectomy
or diagnosis of ovarian cancer were excluded from the study
population. Cases included 50 consecutively recruited patients
with ovarian (n=45), fallopian tube (n=1), and peritoneal cancer
(n=4). Control groups included healthy controls (n=36), surgical
controls (n=14), and benign controls (n=30). The validation
study was powered to detect a marker with 30% sensitivity at 95%
specificity, or better. Demographics of the patients included in this
study are described in Supplementary Tables S1 and S2.
The healthy, surgical and benign controls used in this study
were selected from larger control populations (n=346, 63, and 38
respectively) to match the cases on age, race, family history of
ovarian and breast cancer [26], and blood collection date. We
used propensity score matching to balance the overall distribution
of the groups [27]. Briefly, a propensity score was estimated by
predicting case status using logistic regression on each of the
variables of interest. After first selecting the case group, individual
controls were selected that most closely matched a randomly
identified member of the case group on the assigned propensity
score until pre-specified numbers for each control group had been
selected.
Participants in the surgical control, benign control and case
populations donated serum specimens either at a pre-surgical
appointment 1 to 39 days prior to surgery or on the day of surgery
after administration of anesthesia but before surgical treatment or
chemotherapy. To maximize the power to detect differences in
marker levels due to conditions of collection, we included
specimens collected both on the day of surgery and at the pre-
surgical appointment from the same patient (n=30) whenever
possible. Participants in the healthy control population donated
blood at a regular mammography screening appointment.
Laboratory methods
Prolactin and MIF Assays Serum levels of prolactin and MIF
were measured by ELISA using kits acquired from Diagnostic
Systems Laboratories (Webster, TX) and Onco Detectors
International LLC (Bethesda, MD) respectively. Assays were per-
formed according to manufacturer’s instructions. The concentra-
tions of human prolactin and MIF were determined using a linear
standard curve that was constructed by plotting the mean
absorbance against the known concentration for each reference
standard. See Text S1 for details.
CA 125 Assay Serum levels of CA 125 were measured by
bead-based immunoassays as previously described [28] using anti-
CA 125 mouse monocolonal antibodies 6306 (capture) and 652
(detection) acquired from Research Diagnostics, Inc (RDI,
Flanders, NJ). Readings from the immunoassay were normalized
and then z-scores were calculated by centering and scaling
observations so that healthy controls have mean 0 and variance 1.
See Text S1 for details.
Specimens were randomized onto two plates with 80 specimens
each, and laboratory personnel were blinded to case status at all
times.
Statistical analysis
Receiver operating curves (ROC) were used to determine if serum
marker concentrations discriminated between cases and healthy
controls [29]. The area under each ROC curve (AUC) was
calculatedandsignificanceformarkerdiscrimination (AUCdifferent
from 0.5) was determined using the Mann-Whittney U statistic.
ROC curves for healthy control samples and case samples collected
either prior to surgery or on the day of surgery for each marker were
compared using the method described by Metz et al [30].
To evaluate whether marker levels differed between case and
control groups after adjusting for conditions of blood collection, we
fitted multiple linear regression models to each marker as the
dependent variable with indicator variables for each case/control
population and an indicator variable for conditions of blood
sample collection (clinic visit or in surgery) as independent
Draw Conditions and Biomarkers
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th woman at time t was:
Marker leveli,t~Case=Control Statusiz
Collection Conditioni,tzErrori,t
The reference group in each model is the healthy control group.
This model can potentially separate the components of variance
due to conditions of sample collection and presence of malignancy.
In particular, for markers that elevate due to the presence of
ovarian cancer and are also affected by the conditions of blood
collection, each effect can be estimated from the model
parameters. Regressions were performed using Generalized
Estimating Equations (GEE) methods to avoid bias in estimates
of standard errors because marker levels were measured twice for
30 women in the study.
P-values for differences between partially correlated ROC
curves were calculated with the ROCKIT software package[31]
using the bivariate test. All other calculations were performed
using the R statistical programming language[32].
RESULTS
Marker levels from each case/control group collected in surgery
and at the pre-surgical clinic visit are shown in Figure 1 and
summarized in Table 1. ROC analysis showed that CA 125 and
MIF concentrations discriminate between healthy controls and
cases collected either at surgery or 1 to 39 days prior to surgery
(figure 2a ,b; p,0.05 for each marker and condition). Moreover,
the AUCs were not significantly different between the two
collection conditions (figure 2a,b; p=0.297 and 0.416
respectively).
Prolactin levels were highly elevated in the case specimens
collected at surgery (figure 1c) and prolactin levels discriminated
between case specimens collected at surgery and healthy controls
with high sensitivity and specificity (figure 2c, dotted line).
However, this difference disappeared when we compared case
specimens collected 1 to 39 days prior to surgery to the healthy
controls (figure 2c, solid line). The AUC for discriminating
between cases and controls was significantly lower in specimens
collected in the short interval prior to surgery than for the
specimens obtained at surgery (figure 2c, pdifference in AUC,
Figure 1. Prolactin, MIF and CA 125 levels stratified by population and surgical status. Dotted lines connect surgical and pre-surgical marker levels
measured within the same women under both surgical and non-surgical conditions
doi:10.1371/journal.pone.0001281.g001
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PLoS ONE | www.plosone.org 3 December 2007 | Issue 12 | e12810.0005). Moreover, serum prolactin levels did not discriminate
between healthy controls and case specimens collected 1 to
39 days prior to surgery (figure 2c, solid line AUC=0.497).
We used multiple linear regression models to examine whether
differences in marker levels were associated with case status and/
or with conditions of blood sample collection. In the regression
models, CA 125 and MIF concentrations were not significantly
affected by the conditions of blood collection (table 2, p=0.60 and
0.71 respectively) and were elevated in the cases relative to the
healthy controls (table 2, p,0.005 for each marker). Prolactin
levels, however, were significantly increased in serum samples
collected at surgery (table 2, p,0.005) and after adjusting for
conditions of blood collection, prolactin was not elevated in cases
relative to healthy controls (table 2, p=0.69). These data suggest
that the differences observed with prolactin can be attributed
entirely to blood collection conditions, with no residual signal
associated with malignancy.
DISCUSSION
The approach of using commercially available assays to validate
candidate biomarkers is very promising. However, results can be
misleading if conditions of the blood sample collection for cases
and controls are not standardized or otherwise accounted for. We
show here that serum prolactin levels are strongly influenced by
the conditions of blood collection and that prolactin does not
discriminate between cancer and non-cancer patients in serum
specimens collected similarly in a clinic setting. In contrast, CA
125 and MIF were not affected by the conditions of blood
collection; both markers discriminated between cases and controls
Figure 2. ROC curves comparing marker concentrations in cases to healthy controls. Case specimens were obtained either at surgery (surgical
comparison; dashed line) or 1 to 39 days prior to surgery (pre-surgical comparison; solid line). The pre-surgical comparison suggests that prolactin
levels do not discriminate between women with and without cancer in the clinic setting. * indicates AUC different from 0.5 at alpha=0.05
significance level (Mann Whitney U test)
doi:10.1371/journal.pone.0001281.g002
Table 1. Summary of marker levels by case/control group and collection conditions.
..................................................................................................................................................
Collection Conditions
1 to 39 Days Before Surgery At Surgery
Marker Case/Control Group n median (5
th,9 5
th percentile) n Median (5
th,9 5
th percentile)
CA 125 (z-Score) Healthy Control 36 20.335 (20.747, 4.702 ) – –
Surgical Control 2 20.396 (20.612, 20.18 ) 14 20.369 (20.747, 0.262 )
Benign Control 13 20.276 (20.814, 3.774 ) 30 20.327 (20.814, 10.084 )
Cancer 19 30.198 (0.112, 135.667 ) 46 16.151 (20.473, 350.168 )
MIF (ng/mL) Healthy Control 36 0.5 (0.2, 1.6 ) – –
Surgical Control 2 4.1 (1.3, 6.8 ) 14 0.4 (0.1, 1.8 )
Benign Control 13 0.7 (0.3, 1.3 ) 30 0.6 (0.2, 1.7 )
Cancer 19 1 (0.5, 2.1 ) 46 1 (0.5, 4.1 )
Prolactin (ng/mL) Healthy Control 36 9.9 (4.9, 29.3 ) – –
Surgical Control 2 15.8 (11.8, 19.7 ) 14 108.1 (10.4, 246.2 )
Benign Control 13 7.7 (5, 78.1 ) 30 68.6 (17.3, 245.6 )
Cancer 19 10.8 (3.9, 24.3 ) 46 99.2 (20, 236.8 )
Serum specimens were collected from healthy controls at a regular mammography screening appointment. Specimens were collected from the remaining populations
either at a pre-surgical appointment 1 to 39 days prior to surgery or on the day of surgery after administration of anesthesia but before the surgical procedure.
doi:10.1371/journal.pone.0001281.t001
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PLoS ONE | www.plosone.org 4 December 2007 | Issue 12 | e1281irrespective of whether serum specimens were collected at surgery
or in a short interval prior to surgery.
Thisfindingisconsistentwithpreviousreportsthatprolactinlevels
elevate during surgery and post-operatively in female patients
undergoing surgery with halothane (general) anesthesia [33].
Prolactin levels are also elevated in rats undergoing general
anesthesia with pentobarbital, regardless of surgery [34]. In our
study, specimens collected on the day of surgery were obtained after
general anesthesia was administered but before any incisions were
made. Serum prolactin levels at surgery may have been affected by
anesthesia or by other conditions of surgery such as stress [20].
In multiple linear regression models, differences in CA125 and
MIF levels were associated with case status but not by the
conditions of sample ascertainment. For prolactin, the reverse was
true suggesting that prolactin levels are affected by the conditions
of surgery and may not be a marker of ovarian cancer. These
multivariate analyses complemented the ROC analyses by
adjusting for the conditions of blood collection, thus allowing for
the possibility that a marker signals malignancy despite being
affected by the conditions of blood collection. Adjustment for
collection conditions in the analysis is useful more generally when
blood samples collected under identical conditions are not
available from every participant in a study.
The use of multiple sources of control specimens collected under
various conditions may alert researchers to potential biases. We
have demonstrated that permitting collection conditions to vary in
cases and controls but using correct annotations may alert
researchers to potential problems. Whenever it is not feasible to
obtain multiple collections from cases (both within and outside of
surgery) the use of surgical controls can be used as a screen for the
possible effects of collection condition. For example, it can be seen
in figure 1c that prolactin levels are higher in the control groups
where samples were collected at surgery than in healthy controls,
again suggesting that elevated prolactin levels may not be specific
to malignancy.
The limited availability of pre-clinical specimens from ovarian
cancer patients presents a significant challenge to researchers
trying to discover or validate novel biomarkers for early detection.
The majority of specimens from cancer patients that are available
for research are not collected from women or clinicians who are
blind to their impending diagnosis. Our results illustrate that biases
between case and control populations can lead to false positive
experimental results and that controlling for conditions of blood
collection can reduce false discovery and false validation in
biomarker experiments. It is important to detect, and whenever
possible to correct for, biases in conditions of blood collection
when attempting to discover and validate novel biomarkers.
SUPPORTING INFORMATION
Table S1 Summary of patient demographics by case status
Found at: doi:10.1371/journal.pone.0001281.s001 (0.03 MB
DOC)
Table S2 Summary of ovarian cancers by stage and histology
Found at: doi:10.1371/journal.pone.0001281.s002 (0.03 MB
DOC)
Text S1 Detailed Descriptions of Assay Procedures
Found at: doi:10.1371/journal.pone.0001281.s003 (0.03 MB
DOC)
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Table 2. Results from the multiple linear regression models
..................................................................................................................................................
Marker Variable Level Estimate Std Err p-Value
CA125 Blood Collection Conditions At Clinic (Reference)
In Surgery 3.18 6.05 0.6
Case/Control Group Healthy Control (Reference)
Surgical Control 23.11 5.31 0.58
Benign Control 21.87 4.24 0.66
Ovarian Cancer 39.43 7.14 ,0.005
MIF Blood Collection Conditions At Clinic (Reference)
In Surgery 20.09 0.25 0.71
Case/Control Group Healthy Control (Reference)
Surgical Control 0.46 0.65 0.48
Benign Control 0.11 0.2 0.59
Ovarian Cancer 0.67 0.22 ,0.005
Prolactin Blood Collection Conditions At Clinic (Reference)
In Surgery 93.23 8.82 ,0.005
Case/Control Group Healthy Control (Reference)
Surgical Control 15.23 20.28 0.45
Benign Control 0.45 11.49 0.97
Ovarian Cancer 2.37 5.97 0.69
Multiple linear regression models were fitted to each marker as the dependent variable with indicator variables for each case/control population and an indicator
variable for conditions of blood sample collection (clinic visit or in surgery) as independent variables. GEE methods were used to avoid bias in estimates of standard
errors because marker levels were measured twice for 30 women in the study
doi:10.1371/journal.pone.0001281.t002
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